23:34 , Oct 3, 2018 |  BC Extra  |  Politics & Policy

Phage display founders win Nobel for chemistry

The 2018 Nobel Prize for Chemistry was awarded to three scientists for their work on directed evolution of proteins and enzymes, which led to the development of human antibody-based therapeutics. The first, Humira adalimumab from...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

BIL-010t: Phase I data

A single-arm, open-label, U.S. Phase I trial in 21 patients with a histologically confirmed BCC lesion within the previous 4 weeks showed that topical BIL-010t for 28 days was well tolerated with mild to moderate...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Financial News

Biosceptre International Ltd completes venture financing

Biosceptre International Ltd ., Cambridge, U.K.   Business: Cancer   Date completed: 2014-07-09   Type: Venture financing   Raised: A$5 million ($4.7 million)   Investors: Existing investors  ...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Company News

Biosceptre board of directors update

Biosceptre International Ltd. , North Ryde, Australia   Business: Cancer   Appointed: Alan Bootes as chairman, formerly global manager at Pfizer Inc.  ...
08:00 , Jan 8, 2007 |  BioCentury  |  Strategy

Beyond the land Down Under

With a big infusion of cash coming in via its prescient investment in Domantis Ltd. , Peptech Ltd. aims to provide a new benchmark for the cluster of Australian players aiming to play in global...
08:00 , Dec 11, 2006 |  BC Week In Review  |  Company News

Peptech, Scancell Ltd. deal

PTD acquired Scancell for £2 million ($4 million) in cash and up to £2.9 million ($5.6 million) in milestones for each Scancell product that enters Phase I trials. The milestones may be paid in either...
00:37 , Oct 5, 2005 |  BC Extra  |  Company News

Peptech names Chiplin CEO

Peptech Ltd. (ASX:PTD) hired John Chiplin as CEO and a director, effective in January 2006. Chiplin will take over from Mel Bridges, who will continue as chairman. Previously, Chiplin was CEO of ITI Life Sciences...
07:00 , Aug 29, 2005 |  BC Week In Review  |  Clinical News

Prostate cancer test diagnostic data

Data from an Australian trial in 850 prostate tissue biopsies showed that the prostate cancer test was able to differentiate between malignant and non-malignant tumors with high accuracy. PTD is developing this antibody detection method...
07:00 , Jul 25, 2005 |  BC Week In Review  |  Company News

Domantis, Biosceptre International, Peptech deal

Domantis will develop therapeutic and in vivo diagnostic products against an oncology target from a JV between PTD and Biosceptre. PTD is responsible for preclinical and clinical development, while the JV is responsible for commercialization....